Anti-Human CD370/CLEC9A VHH (SAA2549)
The latest innovation in biotechnology that revolutionizes the study of immune cells.
This powerful single-domain antibody, also known as Nanobody, specifically targets CD370, also known as CLEC9A, a transmembrane protein expressed on dendritic cells. CD370 plays a crucial role in the activation of immune responses and has been linked to various diseases, making it a valuable target for research and therapeutic development.
The Anti-Human CD370/CLEC9A VHH (SAA2549) effectively binds to CD370, blocking its interaction with other immune cells and modulating its function. This results in a more precise and efficient manipulation of dendritic cells, allowing for a deeper understanding of their role in the immune system.
This versatile antibody has a wide range of applications in both basic research and clinical studies. In the laboratory, it can be used for flow cytometry, immunohistochemistry, and Western blotting. Its high specificity and sensitivity make it an ideal tool for identifying and isolating dendritic cells in various tissues and samples.
In addition, the Anti-Human CD370/CLEC9A VHH (SAA2549) has shown promising results in pre-clinical studies as a potential therapeutic agent for autoimmune diseases, cancer, and infectious diseases. By targeting CD370, it can modulate the immune response and potentially improve treatment outcomes.
Researchers can also utilize this antibody in experimental models to study the role of dendritic cells in disease progression and response to treatment. Its small size and high stability make it an excellent candidate for in vivo studies, allowing for targeted delivery and minimal off-target effects.
In summary, the Anti-Human CD370/CLEC9A VHH (SAA2549) is a cutting-edge tool for studying and manipulating dendritic cells. Its unique properties make it a valuable asset in the field of immunology and offer new possibilities for therapeutic development. Order now and unlock the potential of CD370 in your research.
There are no reviews yet.